Axicabtagene ciloleucel versus standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume.
Locke FL, Oluwole OO, Kuruvilla J, Thieblemont C, Morschhauser F, Salles GA, Rowe SP, Vardhanabhuti S, Winters J, Filosto S, To C, Cheng P, Schupp M, Korn R, Kersten MJ.
Locke FL, et al. Among authors: winters j.
Blood. 2024 Apr 1:blood.2023021620. doi: 10.1182/blood.2023021620. Online ahead of print.
Blood. 2024.
PMID: 38557775